Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749875 | 0.89 | CXCR4 (0.32) | — | |
| SCHEMBL18159240 | 0.84 | — | — | |
| SCHEMBL14749867 | 0.82 | — | — | |
| SCHEMBL18531894 | 0.75 | — | — | |
| SCHEMBL12770345 | 0.73 | OPRM1 (0.30) | OPRM1 | |
| SCHEMBL1587067 | 0.71 | OPRM1 (0.33) | OPRM1KDM4EKMT2A | |
| SCHEMBL21360188 | 0.71 | — | — | |
| SCHEMBL16451669 | 0.71 | KDM4E (0.32) | KDM4EKMT2A | |
| SCHEMBL19966668 | 0.71 | — | — | |
| SCHEMBL15491810 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230146782-A1 | DEOXYCHOLIC ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | HUANG, QIANG (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230146782-A1 | DEOXYCHOLIC ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | HUANG, QIANG (CN) | 2023-05-11 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200369621-A1 | SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20090062297-A1 | Hydroxyalkylarylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070244055-A1 | Conjugates useful in the treatment of prostate cancer | BRADY STEPHEN F | 2007-10-18 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BRADY STEPHEN F | 2007-06-07 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GRIN1, GRIN3A, GRIN2C | OPRM1 33/4885KDM4E 1143/4885KMT2A 394/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | OPRM1 3125/4885KDM4E 1704/4885KMT2A 2924/4885 |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | OPRM1 4224/4885KDM4E 1424/4885KMT2A 1934/4885 |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | OPRM1 4224/4885KDM4E 1424/4885KMT2A 1934/4885 |
| US-20090062297-A1 | Hydroxyalkylarylamide Derivatives | AADAC, HDAC5, HDAC3 | OPRM1 4781/4885KDM4E 313/4885KMT2A 36/4885 |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | OPRM1 4224/4885KDM4E 1424/4885KMT2A 1934/4885 |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | OPRM1 3478/4885KDM4E 1571/4885KMT2A 2441/4885 |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BPHL, KLK3, DNPEP | OPRM1 1966/4885KDM4E 1171/4885KMT2A 154/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | OPRM1 3478/4885KDM4E 1571/4885KMT2A 2441/4885 |
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | HDAC5, AADAC, HDAC6 | OPRM1 4716/4885KDM4E 202/4885KMT2A 27/4885 |
| US-20070244055-A1 | Conjugates useful in the treatment of prostate cancer | BPHL, KLK3, DNPEP | OPRM1 1518/4885KDM4E 1500/4885KMT2A 213/4885 |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | OPRM1 4385/4885KDM4E 181/4885KMT2A 121/4885 |
| US-20200369621-A1 | SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF | SLC6A13, SLC6A11, SLC6A1 | OPRM1 174/4885KDM4E 520/4885KMT2A 574/4885 |
| US-20230146782-A1 | DEOXYCHOLIC ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SLC10A1, NR1H4, CYP7A1 | OPRM1 4083/4885KDM4E 4236/4885KMT2A 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.